BMS-820132
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 19, 2022
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132).
(PubMed, J Med Chem)
- "The synthesis and in vitro and in vivo preclinical pharmacology profiles of 31 and its pharmacokinetics (PK) are described. Based on its promising in vivo efficacy and preclinical ADME and safety profiles, 31 was advanced into human clinical trials."
Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus
January 06, 2011
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
-
BMS; P1, N=72;
Diabetes
1 to 2
Of
2
Go to page
1